{"id":"W1941427190","doi":"10.1517/14656566.2012.689825","title":"Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea","year":2012,"lang":"en","type":"letter","venue":"Expert Opinion on Pharmacotherapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Linagliptin; Medicine; Metformin; Glycemic; Sulfonylurea; Regimen; Type 2 Diabetes Mellitus; Hypoglycemia; Pharmacology; Diabetes mellitus; Internal medicine; Type 2 diabetes; Incretin; Dipeptidyl peptidase-4 inhibitor; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001083446,0.001088458,0.00153817,0.0007791842,0.001229969,0.001383918,0.00103746,0.01321528,0.001999157],"category_scores_gemma":[0.005913373,0.0003720502,0.001402104,0.0007131015,0.001247982,0.001982206,0.0005343375,0.01141024,0.002233492],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002386503,"about_ca_system_score_gemma":0.0008674287,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001061417,"about_ca_topic_score_gemma":0.002986498,"domain_scores_codex":[0.9989294,0.0004013265,0.0001344314,0.0001264942,0.0003001328,0.0001082213],"domain_scores_gemma":[0.9989588,0.0005963607,0.0001150197,0.00004143209,0.0001630896,0.0001252045],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006659566,0.0005442873,0.005511364,0.000732296,0.0001774831,0.2074471,0.0003687399,0.0006213955,0.001756205,0.00793429,0.6383632,0.1358777],"study_design_scores_gemma":[0.001149634,0.0008417587,0.005292542,0.00116563,0.0002304896,0.372651,0.0004541331,0.003578542,0.001303822,0.0154048,0.5978187,0.0001090665],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.01118531,0.02662675,0.002464049,0.9081734,0.03367088,0.0001619137,0.00009525874,0.0001755592,0.01744684],"genre_scores_gemma":[0.06877212,0.03624887,0.004381665,0.732468,0.1440992,0.0002494668,0.0001266379,0.00005937325,0.01359472],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.01321528,"threshold_uncertainty_score":0.01731545,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04079503441523548,"score_gpt":0.3364745502938849,"score_spread":0.2956795158786494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}